- Algernon (AGN) announced that all data from its Phase 2 proof-of-concept study of NP-120 for idiopathic pulmonary fibrosis and chronic cough is now finally reported
- The primary endpoint of the study was to determine the type of change in human trials after 12 weeks
- The company is projecting that topline data will be available in July 2022
- Algernon is a clinical stage pharmaceutical development company investigates safe, approved drugs for new disease applications
- Algernon Pharmaceuticals Inc. (AGN) opened trading at $5.50 per share
Algernon (AGN) announced that all data from its Phase 2 proof-of-concept study is now reported and has been “locked” in the database.
The company studied NP-120 (Ifenprodil) for idiopathic pulmonary fibrosis (IPF) and chronic cough.
The primary endpoint of the IPF portion of the study is to determine the number of patients who have zero reduction in lung function at 12 weeks, while the purpose of the proof-of-concept human trial was to determine the safety and efficacy of Ifenprodil in patients with IPF and its associated cough. The primary endpoint of the chronic cough portion of the study was a 50 per cent reduction in average 24-hour cough count at 12 weeks.
The study began in 2020 and recruited 20 patients in Australia and New Zealand with an established diagnosis of IPF and a persistent cough.
The company is projecting that topline data will be available in July 2022.
Algernon is a clinical stage pharmaceutical development company investigates safe, approved drugs for new disease applications.
Algernon Pharmaceuticals Inc. (AGN) opened trading at $5.50 per share.
